In the news

New frontier in biology: harnessing the power of the repeatome with Dennis Zaller |  Biotech2050 podcast

ROME CEO Rosana Kapeller Named to Forbes "50 Over 50" |  Forbes

ROME honored in Endpoints 11: The top private biotechs in pursuit of new drugs |  Endpoints News

The Mysterious Dark Genome: Panel Featuring Rosana Kapeller, CEO of ROME |  World Medical Innovation Forum

The "Dark Genome" with Dr. Rosana Kapeller-Lieberman |  GV "Theory and Practice" podcast

ROME Among C&EN’s 2021 10 Start-Ups to Watch |  C&EN

Kapeller's ROME bags $77M to strike gold in the backwaters of the genome |  Fierce Biotech

ROME Named to Fierce Biotech's 2020 Fierce 15 |  Fierce Biotech

Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry |  MassBio

Rome snags Merck, Celgene vet Zaller as new CSO |  Fierce Biotech

ROME founder Rosana Kapeller recruits a CSO from the senior ranks of a major league R&D team |  Endpoints News

Companies Strain to Outdo Each Other with Work-from-Home Perks (Think Ukuleles) |  Wall Street Journal

From Rio to Rome: Rosanna Kapeller on The Long Run |  The Timmerman Report

ROME: Tackling repeat DNA for cancer, autoimmunity |  BioCentury

At ROME Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs |  Xconomy

The Road to ROME's Series A |  GV

ROME Therapeutics launches to probe junk DNA for cancer drug discovery |  C&EN

ROME Therapeutics debuts with $50M and Rosana Kapeller at the helm |  Fierce Biotech

GV joins $50 million round in ROME Therapeutics to research ‘junk DNA’ for cancer therapies |  VentureBeat

Nimbus founder Rosana Kapeller has a new company, with $50M and an eye on the ‘repeatome’ |  Endpoints News